Latest MS research news

Latest MS research news | 02 July 2014

Patterns of regional gray matter and white matter atrophy in cortical multiple sclerosis

The study speculates that pathological processes in cortical MS patients could more severely involve the most vulnerable white matter tracts; this might then cause neuronal death and atrophy, which in turn might contribute to cognitive impairment.

From MSIF

Latest MS research news | 02 July 2014

Statins in neurological disorders: an overview and update

In addition to their potent anti-atherosclerotic and cardio-protective effects, studies demonstrate anti-inflammatory and immune-modulatory effects of statins in improving MS and other several neurological disorders.

From MSIF

Latest MS research news | 25 June 2014

Teriflunomide (Aubagio) for the treatment of MS

A growing body of studies support the concept that teriflunomide's immune effects are selective and overall achieve a favorable balance between efficacy (limiting new inflammatory disease activity) and safety (preserving host protective immune responses).

From MSIF

Latest MS research news | 24 June 2014

Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes

The study proposes that cholesterol biomarkers be considered in addition to sun exposure, diet, and vitamin D supplementation as key factors involved in vitamin D status.

From MSIF

Latest MS research news | 24 June 2014

A critical review of the fundamental therapeutic effects of glatiramer acetate

Glatiramer Acetate at a daily subcutaneous dose of 20 mg has been found to alter the natural history of relapsing remitting multiple sclerosis. It also enhances neuroprotective repair processes such as remyeliation and neurogenesis.

From MSIF

Latest MS research news | 17 June 2014

Corpus callosum atrophy correlates with gray matter atrophy in patients with MS

Reliable determination of corpus callosum atrophy is of importance because of the structure’s known relationship with disability and cognitive dysfunction. The article describes an optimized method that reliably quantifies corpus callosum atrophy.

From MSIF

Latest MS research news | 17 June 2014

Alemtuzumab treatment of MS: long-term safety and efficacy

In patients with early active relapsing-remitting disease, two cycles of alemtuzumab, with up to three further cycles triggered by a relapse, lead to a stabilisation of disability in the majority of patients treated over an average seven-year follow-up.

From MSIF

Latest MS research news | 17 June 2014

Localisation of citrullinated proteins in normal appearing white matter and lesions in the central nervous system in MS

This study shows for the first time that high levels of citrullinated proteins were localised in areas of activated macrophages with ongoing demyelination and myelin thinning.

From MSIF

Latest MS research news | 10 June 2014

Retinal nerve fibre layer thickness correlates with brain white matter damage in multiple sclerosis

This study suggests that the relation between retinal nerve fibre layer and fractional anisotropy found in MS is related to disease pathology.

From MSIF

Latest MS research news | 10 June 2014

Hypothalamo-pituitary-adrenal axis activity evolves differentially in untreated versus treated multiple sclerosis

Hypothalamo-pituitary-adrenal hyperactivity in multiple sclerosis appears to increase over time and drift from a central towards an additional adrenal component; this effect is attenuated in the context of immunotherapy.

From MSIF
 

Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial